Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Tumours with homologous recombination (HR) defects become sensitive to PARPi. Here, the authors show that androgen receptor (AR) regulates HR and AR inhibition activates the PARP pathway in vivo, thus inhibition of both AR and PARP is required for effective treatment of high risk prostate cancer.

Guardado en:
Detalles Bibliográficos
Autores principales: Mohammad Asim, Firas Tarish, Heather I. Zecchini, Kumar Sanjiv, Eleni Gelali, Charles E. Massie, Ajoeb Baridi, Anne Y. Warren, Wanfeng Zhao, Christoph Ogris, Leigh-Anne McDuffus, Patrice Mascalchi, Greg Shaw, Harveer Dev, Karan Wadhwa, Paul Wijnhoven, Josep V. Forment, Scott R. Lyons, Andy G. Lynch, Cormac O’Neill, Vincent R. Zecchini, Paul S. Rennie, Aria Baniahmad, Simon Tavaré, Ian G. Mills, Yaron Galanty, Nicola Crosetto, Niklas Schultz, David Neal, Thomas Helleday
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/6dd1f31e993c4c649fd8af898835fe41
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares